How Might Treatment of ALK-positive Non-Small Cell Lung Cancer Change in the Near Future?

Expert Review of Anticancer Therapy - United Kingdom
doi 10.1080/14737140.2016.1226138
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

How Should We Treat Alectinib-Refractory ALK-Positive Non–Small Cell Lung Cancer?

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

The Biology and Treatment of EML4-ALK Non-Small Cell Lung Cancer

European Journal of Cancer
Cancer ResearchOncology
2010English

Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non–Small-Cell Lung Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2016English

Pcn152 - Cost Effectiveness of Alectinib in the First Line Treatment of Advanced Alk-Positive Non-Small Cell Lung Cancer in Turkey

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

The Central Nervous System as a Sanctuary Site in ALK-Positive Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2013English

Economic Impact of Preventing Brain Metastases With Alectinib in ALK-positive Non-Small Cell Lung Cancer

Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2018English

P1.01-009 Clinically Primary and Secondary Resistance to ALK Inhibitors in ALK-Positive Advanced Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2017English

Brigatinib for ALK-positive Metastatic Non-Small-Cell Lung Cancer: Design, Development and Place in Therapy

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2019English

P3.01-30 Treatment Sequencing in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) in Japan

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy